医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Recent Settlement in Promega/Genovis Case Maintains Continued Offering of Promega IdeS/IdeZ Proteases

2016年06月30日 PM03:00
このエントリーをはてなブックマークに追加


 

MADISON, Wis.

A recent settlement between Promega Corporation and Genovis AB maintains full freedom for the continued offering of Promega’s IdeS and IdeZ Proteases for markets worldwide. In November of 2014, Genovis and Hansa Medical AB filed a patent infringement suit in the U.S. While the details of the settlement are confidential, it allows for continued manufacture, sale and support of IdeS and IdeZ by Promega.

These products are used by scientists worldwide for a host of applications including early stage characterization of potential therapeutic antibodies that may someday be important for treating different diseases. The settlement allows that work to continue without interruption.

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 3,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160629006456/en/

CONTACT

Promega Corporation
Penny Patterson
Sr. Director,
Communications
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定
  • オクタファルマ、薬物動態に基づくNuwiq®個別化予防療法(NuPreviq法)に関する新しい臨床データの発表により、血友病A患者への強いコミットメントを浮き彫りに
  • ハーバライフ・ニュートリション、健康的でアクティブな生活を促すリーダーとなれるよう、東南アジアのメンバーを鼓舞